指南与共识前列腺增生与排尿功能障碍

成人非神经源性膀胱过度活动症诊断与治疗:AUA/SUFU指南2019年修订版

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019.
指南 / 共识 · J Urol · 2019-08-08

该指南为成人非神经源性膀胱过度活动症(OAB)的诊断与治疗提供临床框架,证据主要源自2009年AHRQ证据报告并补充至2018年10月的文献。指南根据证据强度A(高)、B(中)、C(低)将声明分为标准、推荐或选项,证据不足时提供临床原则和专家意见。

要点

  • 指南为成人非神经源性OAB的诊断与治疗提供循证框架。
  • 证据强度分为A(高)、B(中)、C(低),声明形式为标准、推荐或选项。
  • 证据不足时提供临床原则和专家意见作为补充指导。

核心结论

  • 指南提供了成人非神经源性OAB诊断、总体管理及各种治疗的循证声明。
  • 随着证据基础增长和新治疗策略出现,诊断和治疗方法预期会发生变化。

研究设计与样本

  • 指南制定机构为AUA/SUFU,原始版本证据主要来自2009年AHRQ证据报告/技术评估第187号,并补充检索至2011年12月的文献。
  • 该指南先后于2014年和2018年进行修订,当前版本反映截至2018年10月发表的相关文献。

关键数值与推荐

  • 当证据充分时,特定治疗的证据体被赋予A(高)、B(中)或C(低)强度评级。
  • 此类声明以标准、推荐或选项的形式提供。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of non-neurogenic overactive bladder (OAB). MATERIALS & METHODS: The primary source of evidence for the original version of this guideline was the systematic review and data extraction conducted as part of the Agency for Healthcare Research and Quality (AHRQ) Evidence Report/Technology Assessment Number 187 titled Treatment of Overactive Bladder in Women (2009). That report was supplemented with additional searches capturing literature published through December 2011. Following initial publication, this guideline underwent amendment in 2014 and 2018. The current document reflects relevant literature published through October 2018. RESULTS: When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate), or C (low). Such statements are provided as Standards, Recommendations, or Options. In instances of insufficient evidence, additional guidance information is provided as Clinical Principles and Expert Opinions. CONCLUSIONS: The evidence-based statements are provided for diagnosis and overall management of OAB, as well as for the various treatments. Diagnosis and treatment methodologies can be expected to change as the evidence base grows and as new treatment strategies become obtainable.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lightner DJ, Gomelsky A, Souter L, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019. PMID: 31039103. doi:10.1097/JU.0000000000000309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。